However, a phase 1 clinical trial of daratumumab in combination with anti-PD-1 mAb (JNJ-63723283) in relapsed and refractory MM (MMY2036, NCT03357952) was terminated due to limited clinical responses with increased adverse events in the combination group compared to daratumumab monotherapy. This evidence concerns the gene PDCD1 and Miyoshi myopathy.